Can Trulicity (Dulaglutide) Cause Weight Loss?
Medically reviewed by Alan Lucks | MD, Alan Lucks MDPC Private Practice - New York on July 17th, 2026.
Published on July 15th, 2026. Updated on July 17th, 2026.
Key takeaways
Dulaglutide does cause real but modest weight loss, typically averaging 1.5 to 4.7 kg depending on dose and individual factors.
Clinical trial averages are lower than many patients expect, so setting realistic expectations before starting Trulicity is important.
GLP-1 medications like semaglutide and tirzepatide tend to produce greater weight loss than dulaglutide in head-to-head comparisons.
Diet quality and physical activity still play a major role in outcomes, even when taking a GLP-1 medication like Trulicity.
Patients unsure whether Trulicity is the right GLP-1 for their weight goals should discuss available alternatives with a licensed clinician.
How Dulaglutide Works in the Body
Trulicity (dulaglutide) belongs to a class of medications called GLP-1 receptor agonists. GLP-1 is a hormone your body naturally releases after eating, and it plays several roles in regulating hunger and blood sugar. Dulaglutide mimics this hormone, signaling to the brain that you feel full even before you have finished a large meal.
Beyond appetite signaling, dulaglutide slows gastric emptying, meaning food moves more slowly from the stomach to the small intestine. This delay helps reduce caloric intake by extending feelings of fullness after meals. The medication also regulates insulin and glucagon release, influencing how the body stores and uses fat over time. Together, these mechanisms create conditions that may support gradual weight reduction alongside better blood sugar control.
What Clinical Trials Show About Weight Outcomes
The AWARD trial series, which examined dulaglutide across multiple doses and patient populations, provides the clearest picture of what to expect. In these studies, patients taking dulaglutide experienced average weight loss ranging from approximately 1.5 kg to 4.7 kg, depending on the dose used and the duration of treatment.
The higher weekly dose of 1.5 mg consistently produced more weight loss than the lower starting dose of 0.75 mg. Most weight reduction occurred gradually over 6 to 12 months of consistent use rather than rapidly in the first few weeks. It is important to understand that weight loss is considered a secondary benefit for patients managing type 2 diabetes, not the primary reason the FDA approved dulaglutide. Patients who enter treatment expecting dramatic results may be surprised by the more moderate outcomes seen in clinical data.
Comparing GLP-1 Medications for Weight Loss
Not all GLP-1 receptor agonists perform equally when it comes to weight outcomes. The table below summarizes average weight loss data from clinical trials and FDA approval status for three commonly discussed options.
Medication |
Average Weight Loss in Trials |
FDA Weight-Loss Approval |
|---|---|---|
Dulaglutide (Trulicity) |
1.5 to 4.7 kg |
Not approved for weight loss |
Semaglutide (Ozempic/Wegovy) |
5 to 15 kg (dose dependent) |
Wegovy approved for obesity |
Tirzepatide (Mounjaro/Zepbound) |
7 to 22 kg (dose dependent) |
Zepbound approved for obesity |
Semaglutide produces significantly greater average weight loss than dulaglutide in head-to-head studies. Tirzepatide, which acts on both GLP-1 and GIP receptors, outperforms both for weight outcomes in clinical data. That said, Trulicity may remain the preferred choice for certain patients based on tolerability, insurance coverage, or cost considerations. The best medication is not always the one with the highest average result; it is the one a patient can consistently afford, tolerate, and stay on long term.
Factors That Influence How Much Weight You May Lose
Several personal and treatment-related variables shape how much weight an individual may lose on dulaglutide. Patients who start with a higher baseline BMI tend to see greater absolute weight reduction, though percentage of body weight lost can vary. Those without prior GLP-1 exposure often respond more strongly than patients who have already used a similar medication.
Diet quality and physical activity level remain important even when taking a GLP-1 medication. Clinical studies consistently show that patients who combine dulaglutide with a structured, reduced-calorie eating plan achieve the best outcomes. The dose titration timeline also matters. Most clinicians start patients on 0.75 mg weekly and increase to 1.5 mg after about four weeks. Reaching and maintaining the higher dose is important for maximizing potential weight loss.
Other medications can complicate results. Insulin and sulfonylureas, which are commonly used alongside dulaglutide in type 2 diabetes management, can promote weight gain and may partially offset the weight-reducing effects of the GLP-1 medication.
Understanding Early Side Effects and Their Impact
Nausea and vomiting are the most frequently reported side effects during the first weeks of taking Trulicity, and they can temporarily reduce food intake more aggressively than the medication alone would. While this may produce some early scale movement, it is not the same as sustainable, metabolically driven weight loss.
These gastrointestinal side effects typically peak during weeks one through four and then diminish as the body adjusts to the medication. For patients who experience persistent nausea or vomiting, a clinician may recommend reducing the dose temporarily. A prolonged lower dose can limit weight loss results over time, which is why managing side effects thoughtfully, rather than simply tolerating them, is worth discussing with a healthcare provider.
Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help ease early GI discomfort without requiring a dose reduction in many cases.
Who Is Most Likely to Benefit from Dulaglutide for Weight
Patients with higher starting body weights tend to see the most meaningful absolute weight reduction on dulaglutide. Those who have not previously tried a GLP-1 medication may also respond more strongly than individuals who have already been on semaglutide or another agent in the same class.
Combining Trulicity with a structured, low-calorie eating plan consistently produces better outcomes in research than taking the medication alone. Patients who approach dulaglutide as one part of a broader lifestyle strategy, rather than a standalone solution, are more likely to see results that feel satisfying rather than disappointing.
For individuals whose primary goal is significant weight loss rather than blood sugar management, a conversation with a clinician about whether a higher-potency option might be a better fit is worth having early. With 22 million AI consultations completed and 99.2% treatment plan alignment with board-certified physicians, Doctronic can help patients explore these questions quickly and affordably.
Frequently Asked Questions
Most patients taking Trulicity may lose roughly 1 to 3 kg within the first three months, though results vary widely based on dose, diet, and starting weight. The higher 1.5 mg weekly dose tends to produce more noticeable changes than the 0.75 mg starting dose. Weight loss usually continues gradually over 6 to 12 months of consistent use.
Ozempic (semaglutide) generally produces significantly greater weight loss than Trulicity (dulaglutide) in head-to-head clinical studies. However, Trulicity may still be a reasonable option for some patients based on tolerability, insurance coverage, or cost. A clinician can help determine which medication best fits your specific health profile and goals.
Trulicity is FDA-approved only for type 2 diabetes management, not as a dedicated weight-loss medication. A doctor may prescribe it off-label in some cases, but patients seeking treatment primarily for weight loss are more likely to be directed toward FDA-approved weight management options such as Wegovy (semaglutide) or Zepbound (tirzepatide).
Some studies suggest dulaglutide may produce modest weight loss in people without type 2 diabetes, but the evidence is less robust than for dedicated weight-loss agents. Without a diabetes diagnosis, insurance coverage for Trulicity is typically limited. People without diabetes seeking GLP-1 therapy for weight loss are usually better candidates for medications specifically approved for obesity.
Research consistently shows that combining Trulicity with a structured, reduced-calorie diet produces the best weight outcomes. Focusing on lean proteins, vegetables, whole grains, and limiting processed foods and added sugars can amplify results. Since Trulicity slows gastric emptying, smaller, more frequent meals may also help manage nausea and support steady, gradual weight reduction.
The Bottom Line
Dulaglutide (Trulicity) does cause meaningful weight loss for many people, but the results are modest compared to newer GLP-1 medications. Clinical trials show an average loss of 1.5 to 4.7 kg, with diet, activity level, and dose all playing significant roles. If weight loss is a primary goal rather than a secondary benefit, options like semaglutide or tirzepatide may be worth exploring with your clinician. Doctronic, the first AI legally authorized to practice medicine, offers free AI consultations and $39 video visits available 24/7, so you can get personalized GLP-1 guidance without a long wait. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get medical advice
Chat Now